Cutaneous T-Cell Lymphoma: Current and Emerging Therapies

INTERVIEW*The NINLARO regimen included NINLARO+lenalidomide+dexamethasone.The Rd regimen included placebo+lenalidomide+dexamethasone. 4 † TOURMALINE-MM1: a global, phase 3, randomized (1:1), double-blind, placebo-controlled study that evaluated the safety and efficacy of NINLARO (an oral PI) vs placebo, both in combination with lenalidomide and dexamethasone, until disease progression or unacceptable toxicity in 722 patients with relapsed and/or refractory multiple myeloma who received 1-3 prior therapies. 1,4